Sekar Kathiresan

Sekar Kathiresan is a physician-scientist and human geneticist, currently serving as a chief executive officer and co-founder of Verve Therapeutics. His research is focused on understanding the genetic risk factors of heart attack and blood lipids to improve cardiac care. His research has led to notable discoveries of genetic mutations which confer resistance to cardiovascular diseases, including the discovery of protective mutations in the ANGPTL3 gene.